So far, some phase 1 clinical trials that use CRISPR technology to modify T-cells ... more about how we ensure our content is accurate and current by reading our editorial policy.

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

Treatment for sickle cell disease, the most common inherited blood disorder in Kenya, has been approved for use in England for older children and adults with a severe form of the disease.The treatment ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO ... gene and we have a lot of IP to cover the use of Regnase-1 in CAR-Ts. But essentially ...

The pair recently used CRISPR to mutate the groundcherry equivalent of the tomato’s SELF-PRUNING gene, to try to rein in the groundcherry’s sprawling shoots (Nat Plants, 4:766–70, 2018). They’ve also ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Until now, CRISPR has been used in trials as an ‘ex vivo’ technique to alter the expression of genes in cells in the lab, which can then be administered to patients as a cell therapy.